-+ 0.00%
-+ 0.00%
-+ 0.00%

Ironwood Q1 FY26 net income swings to USD 40.8 million; revenue rises to USD 106.5 million

PUBT·05/07/2026 11:15:39
Listen to the news
Ironwood Q1 FY26 net income swings to USD 40.8 million; revenue rises to USD 106.5 million
  • Ironwood Pharmaceuticals posted Q1 2026 revenue of USD 106.51 million, up 159% year over year, swinging to GAAP net income of USD 40.77 million, or USD 0.25 per share.
  • LINZESS U.S. net sales climbed 97% year over year to USD 272.53 million on improved net price and 5% demand growth, lifting commercial margin to 76%, up 24 percentage points.
  • Collaboration revenue from LINZESS rose 169% year over year to USD 104.22 million, while total costs and expenses fell 52% to USD 33.93 million.
  • Ironwood maintained 2026 guidance for U.S. LINZESS net sales of USD 1.13 billion to USD 1.18 billion, total revenue of USD 450 million to USD 475 million.
  • Management said strong first-quarter revenue should drive significant operating cash flows in Q2 to support repayment of 2026 convertible senior notes due in June, while site initiations for apraglutide STARS-2 Phase 3 remain on track for Q2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605070705BIZWIRE_USPR_____20260507_BW041613) on May 07, 2026, and is solely responsible for the information contained therein.